 NetScientific PLC AIM:NSCI has noted first-quarter results from its portfolio company PDS Biotechnology, which also has results from key trials upcoming at the 2022 American Society of Clinical Oncology ASCO Annual Meeting in Chicago in June. Abstract 6041 will summarize updates to the preliminary efficacy and safety data from the PDS-sponsored VERSATILE-002 Phase 2 clinical trial, which is evaluating PDS0101 in combination with Mercks anti-PD-1 therapy KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer. 